Protagonist Therapeutics (NASDAQ:PTGX) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Protagonist Therapeutics (NASDAQ:PTGX) from a strong-buy rating to a buy rating in a research report released on Saturday.

PTGX has been the subject of a number of other research reports. Citizens Jmp raised their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Wedbush increased their price target on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Zacks Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. The Goldman Sachs Group reissued a “neutral” rating and set a $110.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Finally, Wolfe Research started coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.71.

Protagonist Therapeutics Trading Down 0.2%

Shares of PTGX stock opened at $145.87 on Friday. The stock has a 50 day simple moving average of $124.30 and a 200-day simple moving average of $105.22. The company has a market cap of $9.38 billion, a price-to-earnings ratio of 141.62 and a beta of 1.78. Protagonist Therapeutics has a 12-month low of $50.49 and a 12-month high of $148.00.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm had revenue of $213.47 million for the quarter, compared to the consensus estimate of $212.03 million. Protagonist Therapeutics’s revenue for the quarter was up 3746.8% on a year-over-year basis. On average, equities analysts forecast that Protagonist Therapeutics will post 3.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. The trade was a 53.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares in the company, valued at $52,410,617.36. This represents a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 102,000 shares of company stock worth $10,436,340. 5.19% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics during the fourth quarter worth about $27,000. Harbor Investment Advisory LLC acquired a new position in shares of Protagonist Therapeutics in the second quarter valued at approximately $89,000. EverSource Wealth Advisors LLC raised its position in shares of Protagonist Therapeutics by 63.0% in the first quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $96,000 after buying an additional 352 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in shares of Protagonist Therapeutics by 222.4% during the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after buying an additional 656 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Key Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Protagonist reported quarterly earnings of $2.29 per share, exceeding the $2.27 consensus estimate, while revenue of $213.5 million also topped expectations. The results helped PTGX reach a new one-year high. Protagonist Therapeutics Reaches New 1-Year High on Earnings Beat
• Positive Sentiment: Citigroup raised its price target for PTGX to $175, implying additional upside from recent trading levels and signaling continued confidence in the company’s outlook. Citigroup Raises Protagonist Therapeutics Price Target
• Positive Sentiment: Zacks said rising earnings estimates could support further near-term gains, adding to the bullish momentum following the company’s strong results. Surging Earnings Estimates Signal Upside for Protagonist Therapeutics
• Neutral Sentiment: Wall Street Zen listed PTGX at a Buy rating, although the article’s “downgraded” wording makes the precise rating change unclear. Protagonist Therapeutics Rating Report
• Negative Sentiment: HC Wainwright cut its 2026 EPS forecast to $4.00 from $4.72 and reduced its Q3 estimate to $2.55 from $2.88. It also projects losses in Q4 2026, 2027 and 2028, which highlights potential earnings volatility despite the current-year consensus estimate of $3.69 per share.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.